Hangzhou Tigermed Consulting Co., Ltd (HNGZY)

Market Cap	5.38B +0.1%
Revenue (ttm)	1.03B +8.7%
Net Income	111.85M +129.9%
EPS	0.13 +135.5%
Shares Out	n/a
PE Ratio	48.11
Forward PE	30.07
Dividend	0.01 (0.33%)
Ex-Dividend Date	Jun 22, 2026

Volume	n/a
Open	4.000
Previous Close	4.000
Day's Range	4.000 - 4.000
52-Week Range	4.000 - 4.300
Beta	0.43
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About HNGZY

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, includ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 11,130
• Stock Exchange: OTCMKTS
• Ticker Symbol: HNGZY

Financial Performance

In 2025, HNGZY's revenue was 6.83 billion, an increase of 3.48% compared to the previous year's 6.60 billion. Earnings were 887.89 million, an increase of 119.15%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error